152 related articles for article (PubMed ID: 37951531)
21. Application of INSM1 in Diagnosis and Grading of Laryngeal Neuroendocrine Carcinoma.
Yuan C; Jiao F; Zhai C; Zhang J; Wang S; Zhu L
Laryngoscope; 2021 Oct; 131(10):E2662-E2668. PubMed ID: 33847383
[TBL] [Abstract][Full Text] [Related]
22. Neuroendocrine differentiation in a large series of genetically-confirmed Ewing's sarcoma family tumor: Does it provide any diagnostic or prognostic information?
Machado I; Navarro S; López-Guerrero JA; Verdini L; Picci P; Giner F; Llombart-Bosch A
Pathol Res Pract; 2021 Mar; 219():153362. PubMed ID: 33610950
[TBL] [Abstract][Full Text] [Related]
23. Neuroendocrine neoplasms of the pancreas: diagnosis and pitfalls.
Konukiewitz B; Jesinghaus M; Kasajima A; Klöppel G
Virchows Arch; 2022 Feb; 480(2):247-257. PubMed ID: 34647171
[TBL] [Abstract][Full Text] [Related]
24. Expression of novel neuroendocrine markers in breast carcinomas: a study of INSM1, ASCL1, and POU2F3.
Zhong E; Pareja F; Hanna MG; Jungbluth AA; Rekhtman N; Brogi E
Hum Pathol; 2022 Sep; 127():102-111. PubMed ID: 35690220
[TBL] [Abstract][Full Text] [Related]
25. Expression of Insulinoma-Associated Protein 1 (INSM1) and Orthopedia Homeobox (OTP) in Tumors with Neuroendocrine Differentiation at Rare Sites.
Roy M; Buehler DG; Zhang R; Schwalbe ML; Baus RM; Salamat MS; Lloyd RV; Rosenbaum JN
Endocr Pathol; 2019 Mar; 30(1):35-42. PubMed ID: 30523500
[TBL] [Abstract][Full Text] [Related]
26. Synaptophysin and chromogranin A expression analysis in human tumors.
Uhlig R; Dum D; Gorbokon N; Menz A; Büscheck F; Luebke AM; Hube-Magg C; Hinsch A; Höflmayer D; Fraune C; Möller K; Bernreuther C; Lebok P; Weidemann S; Lennartz M; Jacobsen F; Clauditz TS; Sauter G; Wilczak W; Steurer S; Burandt E; Krech R; Krech T; Marx AH; Simon R; Minner S
Mol Cell Endocrinol; 2022 Sep; 555():111726. PubMed ID: 35921917
[TBL] [Abstract][Full Text] [Related]
27. INSM1 Is a Highly Specific Marker of Neuroendocrine Differentiation in Primary Neoplasms of the Gastrointestinal Tract, Appendix, and Pancreas.
McHugh KE; Mukhopadhyay S; Doxtader EE; Lanigan C; Allende DS
Am J Clin Pathol; 2020 May; 153(6):811-820. PubMed ID: 32128564
[TBL] [Abstract][Full Text] [Related]
28. INSM1 Expression in Breast Neoplasms with Neuroedocrine Features.
Metovic J; Castellano I; Marinelli E; Osella-Abate S; Sapino A; Cassoni P; Papotti M
Endocr Pathol; 2021 Dec; 32(4):452-460. PubMed ID: 34008122
[TBL] [Abstract][Full Text] [Related]
29. INSM1 immunostaining in solid papillary carcinoma of the breast.
Kudo N; Takano J; Kudoh S; Arima N; Ito T
Pathol Int; 2021 Jan; 71(1):51-59. PubMed ID: 33156579
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic Utility of INSM1 in Medullary Thyroid Carcinoma.
Seok JY; Kang M; De Peralta-Venturina M; Fan X
Int J Surg Pathol; 2021 Sep; 29(6):615-626. PubMed ID: 33650906
[TBL] [Abstract][Full Text] [Related]
31. INSM1 is a useful neuroendocrine marker to differentiate pancreatic serous cystadenoma from pancreatic well-differentiated neuroendocrine tumors in cytology and surgical specimens.
Chi Z; Xu J; Karamchandani DM; Peng L
Ann Diagn Pathol; 2024 Aug; 71():152304. PubMed ID: 38614035
[TBL] [Abstract][Full Text] [Related]
32. Insulinoma-associated protein 1 expression in primary and metastatic neuroendocrine neoplasms of the gastrointestinal and pancreaticobiliary tracts.
González I; Lu HC; Sninsky J; Yang C; Bishnupuri K; Dieckgraefe B; Cao D; Chatterjee D
Histopathology; 2019 Oct; 75(4):568-577. PubMed ID: 31077609
[TBL] [Abstract][Full Text] [Related]
33. Syntaxin 1: A Novel Robust Immunophenotypic Marker of Neuroendocrine Tumors.
Kővári B; Turkevi-Nagy S; Báthori Á; Fekete Z; Krenács L
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32059362
[TBL] [Abstract][Full Text] [Related]
34. Exploration of INSM1 and hASH1 as additional markers in lung cytology samples of high-grade neuroendocrine carcinoma with indeterminate neuroendocrine differentiation.
Rothrock AT; Stewart J; Li F; Racila E; Amin K
Diagn Cytopathol; 2022 May; 50(5):230-234. PubMed ID: 35147301
[TBL] [Abstract][Full Text] [Related]
35. Clinical Routine Application of the Second-generation Neuroendocrine Markers ISL1, INSM1, and Secretagogin in Neuroendocrine Neoplasia: Staining Outcomes and Potential Clues for Determining Tumor Origin.
Juhlin CC; Zedenius J; Höög A
Endocr Pathol; 2020 Dec; 31(4):401-410. PubMed ID: 32813226
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathologic features and diagnostic challenges of small cluster pattern appendiceal neuroendocrine tumors.
Gertsen B; Arshi J; Li RX; Findeis-Hosey JJ; Huber AR; Hao Y
Ann Diagn Pathol; 2024 Apr; 69():152250. PubMed ID: 38142627
[TBL] [Abstract][Full Text] [Related]
37. Immunosensitivity and specificity of insulinoma-associated protein 1 (INSM1) for neuroendocrine neoplasms of the uterine cervix.
Kuji S; Endo A; Kubota M; Uekawa A; Kawakami F; Mikami Y; Koike J; Suzuki N
J Gynecol Oncol; 2023 Jan; 34(1):e1. PubMed ID: 36245222
[TBL] [Abstract][Full Text] [Related]
38. Neuroendocrine Markers Insulinoma-Associated Protein 1, Chromogranin, Synaptophysin, and CD56 Show Rare Positivity in Adenocarcinoma Ex-Goblet Cell Carcinoids.
Yang C; Gonzalez I; Zhang L; Cao D
Gastroenterology Res; 2019 Jun; 12(3):120-127. PubMed ID: 31236152
[TBL] [Abstract][Full Text] [Related]
39. Insulinoma-associated protein 1 (INSM1) is a useful marker for pancreatic neuroendocrine tumor.
Tanigawa M; Nakayama M; Taira T; Hattori S; Mihara Y; Kondo R; Kusano H; Nakamura K; Abe Y; Ishida Y; Okabe Y; Hisaka T; Okuda K; Fujino K; Ito T; Kawahara A; Naito Y; Yamaguchi R; Akiba J; Akagi Y; Yano H
Med Mol Morphol; 2018 Mar; 51(1):32-40. PubMed ID: 28849340
[TBL] [Abstract][Full Text] [Related]
40. Selected markers (chromogranin A, neuron-specific enolase, synaptophysin, protein gene product 9.5) in diagnosis and prognosis of neuroendocrine pulmonary tumours.
Kasprzak A; Zabel M; Biczysko W
Pol J Pathol; 2007; 58(1):23-33. PubMed ID: 17585539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
